Innoviva Signs Exclusive Distribution Agreement with Dr. Reddy's for XACDURO
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (INVA), announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories (RDY) for the development and commercialization of XACDURO, co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent States countries. Under the terms of the agreement, Dr. Reddy's will be responsible for development, regulatory and commercialization activities in the licensed territory. Innoviva Specialty Therapeutics will retain rights to XACDURO in all unlicensed territories and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales in the licensed territory.
